Daryl Tan-Yeung Lau, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B, Chronic | 32 | 2024 | 410 | 6.300 |
Why?
|
| Hepatitis B virus | 33 | 2024 | 527 | 4.750 |
Why?
|
| Hepatitis B Surface Antigens | 13 | 2024 | 294 | 3.090 |
Why?
|
| Hepatitis B | 14 | 2023 | 704 | 2.810 |
Why?
|
| Hepatitis B e Antigens | 15 | 2023 | 133 | 2.040 |
Why?
|
| Hepatitis B Antibodies | 4 | 2024 | 155 | 1.680 |
Why?
|
| Hepatitis B Core Antigens | 6 | 2023 | 90 | 1.410 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2022 | 2293 | 1.230 |
Why?
|
| Antiviral Agents | 29 | 2023 | 3048 | 1.220 |
Why?
|
| Hepatitis C, Chronic | 9 | 2022 | 1027 | 1.130 |
Why?
|
| DNA, Viral | 19 | 2023 | 2195 | 1.070 |
Why?
|
| Liver Neoplasms | 10 | 2022 | 4308 | 0.980 |
Why?
|
| Cryoglobulinemia | 1 | 2022 | 84 | 0.780 |
Why?
|
| Hepatitis C | 7 | 2022 | 1579 | 0.740 |
Why?
|
| Hepacivirus | 11 | 2022 | 1330 | 0.690 |
Why?
|
| Virus Activation | 2 | 2018 | 319 | 0.640 |
Why?
|
| Interferon-alpha | 6 | 2014 | 907 | 0.640 |
Why?
|
| Superinfection | 1 | 2018 | 63 | 0.600 |
Why?
|
| Liver Cirrhosis | 9 | 2022 | 1932 | 0.600 |
Why?
|
| Hepatitis E | 1 | 2018 | 76 | 0.560 |
Why?
|
| Alanine Transaminase | 10 | 2021 | 602 | 0.550 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2022 | 709 | 0.530 |
Why?
|
| Liver | 10 | 2020 | 7513 | 0.500 |
Why?
|
| Kupffer Cells | 2 | 2013 | 143 | 0.500 |
Why?
|
| Developing Countries | 2 | 2024 | 2862 | 0.390 |
Why?
|
| RNA, Viral | 4 | 2021 | 2839 | 0.370 |
Why?
|
| Interferons | 5 | 2019 | 702 | 0.350 |
Why?
|
| Interferon Regulatory Factor-3 | 2 | 2008 | 141 | 0.340 |
Why?
|
| Aspartate Aminotransferases | 4 | 2015 | 411 | 0.270 |
Why?
|
| Hepatitis A Antibodies | 1 | 2005 | 19 | 0.260 |
Why?
|
| Viral Load | 7 | 2019 | 3328 | 0.240 |
Why?
|
| Immune Tolerance | 1 | 2012 | 2307 | 0.220 |
Why?
|
| Platelet Count | 3 | 2015 | 782 | 0.220 |
Why?
|
| Genotype | 8 | 2021 | 12983 | 0.220 |
Why?
|
| North America | 3 | 2021 | 1281 | 0.210 |
Why?
|
| Immunity, Innate | 2 | 2012 | 3044 | 0.210 |
Why?
|
| Cryoglobulins | 1 | 2022 | 58 | 0.200 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2009 | 227 | 0.200 |
Why?
|
| Mutation | 2 | 2024 | 30006 | 0.200 |
Why?
|
| Antigens, Surface | 2 | 2023 | 1607 | 0.190 |
Why?
|
| Humans | 65 | 2024 | 761098 | 0.190 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 223 | 0.190 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2020 | 30 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2024 | 364 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1703 | 0.170 |
Why?
|
| Biopsy | 7 | 2020 | 6781 | 0.170 |
Why?
|
| Adult | 33 | 2024 | 221083 | 0.170 |
Why?
|
| Liver Function Tests | 3 | 2019 | 524 | 0.160 |
Why?
|
| Polyethylene Glycols | 3 | 2022 | 1187 | 0.160 |
Why?
|
| Adenine | 1 | 2004 | 986 | 0.160 |
Why?
|
| Virus Replication | 6 | 2022 | 2426 | 0.160 |
Why?
|
| Liver Diseases | 2 | 2013 | 1300 | 0.150 |
Why?
|
| Female | 36 | 2024 | 392458 | 0.150 |
Why?
|
| Actins | 1 | 2005 | 2046 | 0.150 |
Why?
|
| Hepatitis B Vaccines | 1 | 2019 | 177 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 346 | 0.140 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 181 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 5478 | 0.140 |
Why?
|
| Viremia | 1 | 2019 | 707 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 11856 | 0.130 |
Why?
|
| Genetic Variation | 4 | 2021 | 6565 | 0.130 |
Why?
|
| Middle Aged | 23 | 2024 | 220835 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 3196 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 2150 | 0.120 |
Why?
|
| Guanine | 1 | 2016 | 278 | 0.120 |
Why?
|
| Lamivudine | 3 | 2007 | 366 | 0.120 |
Why?
|
| Fatigue | 1 | 2022 | 1550 | 0.120 |
Why?
|
| Electricity | 1 | 2015 | 175 | 0.120 |
Why?
|
| Male | 30 | 2024 | 360675 | 0.120 |
Why?
|
| Microtechnology | 1 | 2014 | 70 | 0.120 |
Why?
|
| Hepatitis B Antigens | 1 | 2013 | 38 | 0.110 |
Why?
|
| Young Adult | 8 | 2024 | 59199 | 0.110 |
Why?
|
| Puerperal Disorders | 1 | 2016 | 301 | 0.110 |
Why?
|
| Hepatocytes | 2 | 2012 | 1231 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 219 | 0.110 |
Why?
|
| Gastroenterology | 1 | 2020 | 580 | 0.110 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 188 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 10203 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9416 | 0.110 |
Why?
|
| Janus Kinases | 1 | 2014 | 248 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 1448 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 1351 | 0.100 |
Why?
|
| Lectins | 1 | 2013 | 489 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 6507 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 261 | 0.090 |
Why?
|
| Prevalence | 3 | 2024 | 15717 | 0.090 |
Why?
|
| Nanostructures | 1 | 2015 | 551 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 4739 | 0.090 |
Why?
|
| Age Factors | 3 | 2022 | 18385 | 0.080 |
Why?
|
| Aged | 10 | 2024 | 169266 | 0.080 |
Why?
|
| Hepatitis C Antigens | 1 | 2009 | 34 | 0.080 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 918 | 0.080 |
Why?
|
| Prediabetic State | 1 | 2015 | 545 | 0.080 |
Why?
|
| Algorithms | 4 | 2021 | 14023 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2012 | 642 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 647 | 0.080 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 158 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 14607 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2014 | 713 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2012 | 557 | 0.080 |
Why?
|
| United States | 9 | 2024 | 72337 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2022 | 381 | 0.080 |
Why?
|
| RNA | 3 | 2023 | 2708 | 0.080 |
Why?
|
| Inflammasomes | 1 | 2013 | 525 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11066 | 0.070 |
Why?
|
| Quantum Dots | 1 | 2009 | 167 | 0.070 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 544 | 0.070 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2009 | 267 | 0.070 |
Why?
|
| Mass Screening | 1 | 2003 | 5425 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 1002 | 0.070 |
Why?
|
| Hepatitis, Chronic | 1 | 2006 | 52 | 0.070 |
Why?
|
| Hepatitis A virus | 1 | 2005 | 16 | 0.060 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 862 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2021 | 54419 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 39121 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2004 | 621 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 58946 | 0.060 |
Why?
|
| Chromatography | 1 | 2003 | 188 | 0.060 |
Why?
|
| Incidence | 4 | 2022 | 21357 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2012 | 3568 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2015 | 18926 | 0.050 |
Why?
|
| Pregnancy | 3 | 2019 | 29872 | 0.050 |
Why?
|
| DNA, Circular | 1 | 2022 | 96 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 615 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4538 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2008 | 789 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1921 | 0.050 |
Why?
|
| Canada | 2 | 2019 | 2125 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3803 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 42217 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2013 | 2279 | 0.050 |
Why?
|
| Adolescent | 5 | 2021 | 88271 | 0.050 |
Why?
|
| ROC Curve | 3 | 2020 | 3582 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 398 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2013 | 4933 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 16572 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2023 | 41486 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 14676 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2018 | 80673 | 0.040 |
Why?
|
| Child | 3 | 2022 | 80134 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 6305 | 0.040 |
Why?
|
| Population Groups | 1 | 2019 | 207 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3725 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 398 | 0.040 |
Why?
|
| Neutropenia | 1 | 2003 | 885 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2018 | 9317 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5841 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3776 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2726 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1696 | 0.030 |
Why?
|
| Carrier State | 1 | 2019 | 522 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2892 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 22157 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2003 | 1354 | 0.030 |
Why?
|
| Transaminases | 1 | 2015 | 199 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2015 | 149 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 273 | 0.030 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2014 | 17 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 658 | 0.030 |
Why?
|
| Time Factors | 3 | 2018 | 39953 | 0.030 |
Why?
|
| Alaska | 1 | 2013 | 69 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 15845 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 15308 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 26068 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13506 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 178 | 0.030 |
Why?
|
| Publishing | 1 | 2020 | 832 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 340 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1892 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 503 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 697 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2013 | 226 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 16947 | 0.030 |
Why?
|
| Cell Line | 2 | 2019 | 15542 | 0.020 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 165 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2018 | 3603 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4565 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2015 | 616 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2018 | 1178 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 455 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2478 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2007 | 8639 | 0.020 |
Why?
|
| Proteins | 1 | 2005 | 5993 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2815 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1176 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2014 | 432 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2014 | 766 | 0.020 |
Why?
|
| Microfluidics | 1 | 2015 | 651 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1121 | 0.020 |
Why?
|
| Chemokines | 1 | 2013 | 956 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 583 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2219 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5869 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2022 | 64670 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 2200 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 1553 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2009 | 290 | 0.020 |
Why?
|
| Survivors | 1 | 1998 | 2369 | 0.020 |
Why?
|
| Prognosis | 2 | 2022 | 29672 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3155 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3509 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3577 | 0.020 |
Why?
|
| Replicon | 1 | 2006 | 34 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 1684 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6312 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8456 | 0.020 |
Why?
|
| Vaccination | 1 | 2018 | 3368 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2007 | 590 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2013 | 12743 | 0.010 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2005 | 173 | 0.010 |
Why?
|
| Base Sequence | 2 | 2005 | 12404 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 20120 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12975 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12058 | 0.010 |
Why?
|
| Computer Systems | 1 | 2004 | 470 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1636 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 3092 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3821 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13254 | 0.010 |
Why?
|
| Public Health | 1 | 2014 | 2671 | 0.010 |
Why?
|
| Gene Expression | 1 | 2014 | 7567 | 0.010 |
Why?
|
| Infant | 2 | 2019 | 36164 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2015 | 6390 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2014 | 23415 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10421 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15915 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7386 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5750 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20600 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3388 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6067 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 36418 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 3620 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 8000 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 7400 | 0.010 |
Why?
|